Maris Hartmanis appointed new CEO of Medivir

Maris Hartmanis appointed new CEO of Medivir

Huddinge, Sweden - Medivir AB (OMX: MVIR), an emerging research-based
specialty pharmaceutical company focused on infectious diseases, today
announces that the board has appointed Maris Hartmanis as new President
and CEO.

Maris Hartmanis replaces Ron Long, who has been President and CEO of
Medivir since 2009. Under Ron Long's leadership, the company has
obtained a clear commercial focus and has taken several important steps
towards the goal of becoming a profitable pharmaceutical company. In
consultation with Ron Long, the board has found the timing appropriate
to hand over the leadership to Maris Hartmanis. In connection with Ron
Long's resignation from his position as CEO, he will also resign from
the board of Medivir.

Maris Hartmanis has a Ph.D. degree and is an Associate Professor in
biochemistry. He has extensive experience from the life science
industry, from senior positions within Gambro, Amersham and Pharmacia
and was appointed CEO of the specialty pharmaceutical company BioPhausia
in 2010. Maris Hartmanis was appointed deputy CEO and COO of Medivir
following Medivir's acquisition of BioPhausia earlier this year.

The chairman of the board, Göran Pettersson, comments: “We are very
happy to welcome Maris Hartmanis as the new CEO of Medivir. We have all
been impressed by Maris' great capacity and competence, both in his role
as CEO of BioPhausia and, now, in Medivir's executive management team as
deputy CEO. Through the appointment of Maris Hartmanis as CEO, we secure
an appropriate succession of the leadership of Medivir and a continued
positive development of Medivir as a research-based specialty
pharmaceutical company. We thank Ron Long for his highly valued
contribution, both as CEO and board member during the past years.”
 

For more information about Medivir, please contact:

Medivir(www.medivir.com (http://www.medivir.com/)):
Rein Piir, CFO &VP Investor Relations                Mobile:
+46 708 537 292

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company
focused on the development of high-value treatments for infectious
diseases. Medivir has world class expertise in polymerase and protease
drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The company's key pipeline asset is
TMC435, a novel protease inhibitor, which is in phase 3 clinical
development for hepatitis C and is partnered with Tibotec
Pharmaceuticals. In June 2011, Medivir acquired the specialty
pharmaceutical company BioPhausia to ensure commercialization of TMC435
in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®
was launched on the US market in February 2011. Xerese®/Xerclear®, which
has been approved in both the US and Europe is partnered with
GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. The rights
in North America, Canada and Mexico have recently been sold to Meda AB.
Medivir has retained the Rx rights for Xerclear®in Sweden and Finland.

Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was submitted
for publication at 8:30a.m. CET on 26 September 2011.

For more information about Medivir, please visit the company's website:
www.medivir.com (http://www.medivir.com/)